Prevalence of nosocomial pneumonia in critically ill patients receiving omeprazole therapy
DOI:
https://doi.org/10.33448/rsd-v14i12.49979Keywords:
Proton Pump Inhibitors, Omeprazole, Healthcare-Associated Pneumonia.Abstract
Proton Pump Inhibitors (PPIs) are drugs used for the prophylaxis of stress ulcers, as well as in other clinical situations that require reduction of gastric hydrochloric acid production. However, evidence suggests that PPIs may increase the risk of pneumonia due to consequent alterations in gastrointestinal microbiota and immune response. Objective: To analyze the association between the use of 40 mg injectable omeprazole and the occurrence of pneumonia. Methodology: Analysis of 48 medical records of patients treated with 40 mg intravenous omeprazole in the Intensive Care Unit of a teaching hospital during 2023 and 2024. Results: Eight cases of pneumonia were identified, predominantly in men aged 51 to 60 years, a group in which four deaths also occurred. Conclusion: Although omeprazole may increase the risk of pneumonia by reducing gastric acidity and favoring bacterial colonization, the study highlights that pneumonia in ICUs is a multifactorial event. Thus, it is concluded that the benefit of omeprazole use outweighs the risks, especially when combined with good clinical practices and individualized monitoring.
References
Albrich, W. C., Rassouli, F., Waldeck, F., Berger, C., & Baty, F. (2019). Influence of older age and other risk factors on pneumonia hospitalization in Switzerland in the pneumococcal vaccine era. Frontiers in Medicine, 6, 286.
Alshamsi, F., et al. (2016). Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: A systematic review and meta-analysis of randomized trials. Critical Care, 20, 120.
Ayhan, Y. E., & Turgut, N. (2025). Ensuring guideline adherence and cost savings in stress ulcer prophylaxis practices in the intensive care unit: a pre-post education study. Journal of Pharmacy & Pharmaceutical Sciences, 28, 14067.
Herardi, R., Syam, A. F., Fauzi, A., Rinaldi, I., Sandra, S., & Arvant, A. Z. (2025). Role of gastric acid suppression therapy in erosive esophagitis: From H2 receptor antagonists, proton pump inhibitors, to potassium-competitive acid blockers. Acta Medica Indonesiana - Indonesian Journal of Internal Medicine, 57(2), 284–292.
Jamulitrat, S., et al. (2004). Stress ulcer prophylaxis and risk of developing ventilator-associated pneumonia. Association for Professionals in Infection Control and Epidemiology.
Jager, C. P. C., et al. (2012). Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Alimentary Pharmacology & Therapeutics, 36, 941–949.
Kasirye, Y., & Islam, T. (2010). Nosocomial pneumonia risk and stress ulcer prophylaxis. Clinical Pulmonary Medicine, 17, 103–105.
Lambert, A. A., Lam, J. O., Paik, J. J., Ugarte-Gil, C., Drummond, M. B., & Crowell, T. A. (2015). Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis. PLoS ONE, 10(6), e0128004.
Lanks, C. W., Musani, A. I., & Hsia, D. W. (2019). Community-acquired pneumonia and hospital-acquired pneumonia. Medical Clinics of North America.
Maret-Ouda, J., Panula, J., Santoni, G., Xie, S., & Lagergren, J. (2023). Proton pump inhibitor use and risk of pneumonia: A self-controlled case series study. Journal of Gastroenterology, 58, 734–740.
Mendes, J. J., et al. (2019). Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. Revista Brasileira de Terapia Intensiva.
Nguyen, P. A., et al. (2020). Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. International Journal for Quality in Health Care, 32(5), 292–299.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria. Editora da UFSM.
Prod’hom, G., et al. (1994). Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. Annals of Internal Medicine, 120, 653–662.
Ramsay, E. N., Pratt, N. L., Ryan, P., & Roughead, E. E. (2013). Proton pump inhibitors and the risk of pneumonia: A comparison of cohort and self-controlled case series designs. BMC Medical Research Methodology, 13, 82.
Ratelle, M., Perreault, S., Villeneuve, J.-P., & Tremblay, L. (2014). Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Canadian Journal of Gastroenterology and Hepatology, 28(6), 330–334.
Reade, M. C., Yende, S., & Angus, D. C. (2011). Revisiting Mars and Venus: Understanding gender differences in critical illness. Critical Care, 15(4), 180.
Silva Júnior, J. C., & Friggi, J. R. (2024). Efeitos do uso crônico dos inibidores da bomba de prótons. Research, Society and Development, 13(4).
Song, T. J., & Kim, J. (2019). Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS ONE, 14(5), e0216750.
Van Vlerken, L. G., Huisman, E. J., van Hoek, B., Renooij, W., de Rooij, F. W. M., Siersema, P. D., & van Erpecum, K. J. (2012). Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation, 42(7), 760–767.
Xie, Y., Yan, Y., Hong, Q., Zheng, H., Cao, L., Li, X., Liu, S., & Chen, H. (2025). Heterogeneous treatment effects of stress ulcer prophylaxis among ICU patients at risk for gastrointestinal bleeding. BMC Medicine, 23(1), 206.
Shitsuka, R. et al. (2014). Matemática fundamental para a tecnologia. (2ed). Editora Érica.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nicoli Liber Baratieri, Clarissa Vasconcelos de Oliveira, Heloísa Gemelli Tansini da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
